CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$1.41 USD
0.00 (0.00%)
Updated May 20, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.71%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Carisma Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 15 | 40 | 27 | 11 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 15 | 40 | 27 | 11 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 104 | 66 | 35 | 32 | 108 |
Income After Depreciation & Amortization | -89 | -26 | -9 | -21 | -108 |
Non-Operating Income | 2 | 2 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -87 | -24 | -9 | -21 | -108 |
Income Taxes | 0 | -4 | -8 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -87 | -20 | 0 | -22 | -108 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -87 | -20 | 0 | -22 | -108 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -85 | 1 | 23 | -21 | -108 |
Depreciation & Amortization (Cash Flow) | 4 | 27 | 32 | 0 | 0 |
Income After Depreciation & Amortization | -89 | -26 | -9 | -21 | -108 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 33.52 | 10.03 | 9.12 | 5.91 | 4.55 |
Diluted EPS Before Non-Recurring Items | -2.59 | 1.00 | -1.60 | -3.00 | -7.80 |
Diluted Net EPS (GAAP) | -2.59 | -2.00 | -0.04 | -3.80 | -23.60 |
Fiscal Year end for Carisma Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 3.40 | 4.29 | 3.83 | 3.56 | 3.24 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.40 | 4.29 | 3.83 | 3.56 | 3.24 |
SG&A, R&D, and Dept/Amort Expenses | 22.91 | 26.74 | 26.17 | 24.53 | 26.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | -19.51 | -22.45 | -22.34 | -20.97 | -22.97 |
Non-Operating Income | 0.53 | -0.18 | 0.94 | 1.18 | -0.08 |
Interest Expense | 0.00 | -1.48 | 0.00 | 0.00 | 1.48 |
Pretax Income | -18.98 | -21.15 | -21.40 | -19.79 | -24.53 |
Income Taxes | 0.00 | -0.20 | 0.00 | 0.09 | 0.11 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -18.98 | -20.96 | -21.40 | -19.88 | -24.64 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -18.98 | -20.96 | -21.40 | -19.88 | -24.64 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 40.94 | 40.39 | 40.29 | 40.26 | 12.78 |
Diluted EPS Before Non-Recurring Items | -0.46 | -0.52 | -0.53 | -0.49 | -1.93 |
Diluted Net EPS (GAAP) | -0.46 | 0.36 | -0.53 | -0.49 | -1.93 |